دورية أكاديمية

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

التفاصيل البيبلوغرافية
العنوان: Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
المؤلفون: Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E, Chow, Laura Q M, Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice
المصدر: Journal of Clinical Oncology; 3/1/2021, Vol. 39 Issue 7, p723-733, 11p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.20.01605